Location History:
- Millersville, MD (US) (1997)
- Severn, MD (US) (1998 - 2005)
Company Filing History:
Years Active: 1997-2005
Title: Antonette C Allen: Innovator in Genetic Research
Introduction
Antonette C Allen is a prominent inventor based in Severn, MD (US). She has made significant contributions to the field of genetics, particularly in relation to the BRCA1 gene, which is crucial for understanding breast and ovarian cancer susceptibility. With a total of 4 patents, her work has paved the way for advancements in gene therapy and genetic testing.
Latest Patents
Allen's latest patents focus on the coding sequences of the human BRCA1 gene. These inventions include isolated coding sequences and the protein sequences they code for. Specifically, her patents detail three coding sequences of the BRCA1 gene, identified as BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3). The patents provide information on their frequencies of occurrence along with the corresponding protein sequences. Additionally, her inventions encompass methods for determining the consensus sequence for any gene and identifying individuals with an increased genetic susceptibility to breast or ovarian cancer due to inherited mutations in their BRCA1 gene. Furthermore, her work includes methods for performing gene therapy and protein therapy using the isolated BRCA1 coding sequences and their functional equivalents.
Career Highlights
Throughout her career, Antonette C Allen has worked with notable companies such as Oncormed, Inc. and Gene Logic, Inc. Her experience in these organizations has contributed to her expertise in genetic research and innovation.
Collaborations
Some of her coworkers include Patricia D Murphy and Christopher P Alvares, who have collaborated with her on various projects related to genetic research.
Conclusion
Antonette C Allen's contributions to the field of genetics, particularly through her patents related to the BRCA1 gene, highlight her role as an innovator in genetic research. Her work not only advances scientific understanding but also has the potential to impact the lives of individuals at risk for breast and ovarian cancer.